Regional comparison of efficacy and safety for vilobelimab in critically ill, invasively mechanically ventilated COVID-19 patients
Background Vilobelimab, a first in class C5a-specific monoclonal antibody, improved 28-day and 60-day mortality in intubated COVID-19 patients in PANAMO, a phase 3 randomised, double-blind, placebo-controlled multicentre study. All-cause mortality was pre-specified to be analysed pooling by region (...
Saved in:
Similar Items
-
Cerebrovascular Complications in Bacterial Meningitis
by: Shahrzad S. Deliran, et al.
Published: (2025-01-01) -
Streptococcus suis Meningitis: A Systematic Review and Meta-analysis.
by: Anusha van Samkar, et al.
Published: (2015-01-01) -
Sex differences in bacterial meningitis and associations with socioeconomic indicators: a systematic review and meta-analysis with metaregression
by: Cornelis N van Ettekoven, et al.
Published: (2025-04-01) -
Intracerebral hemorrhages in adults with community associated bacterial meningitis in adults: should we reconsider anticoagulant therapy?
by: Barry B Mook-Kanamori, et al.
Published: (2012-01-01) -
Diagnostic prediction models for bacterial meningitis in children with a suspected central nervous system infection: a systematic review and prospective validation study
by: Michael W T Tanck, et al.
Published: (2024-08-01)